DUBLIN, Dec. 29, 2022 (GLOBE NEWSWIRE) — The Autism Spectrum Disorder Therapies Market by Therapies, Applications, Distribution Channels and Regions – Global Forecasts 2022 to 2033 Report Added . of ResearchAndMarkets.com Recruitment.
The market size of Autism Spectrum Disorder Treatment is estimated at USD 2,453.2 million in 2022 and is expected to grow at a CAGR of 6.47% during the forecast period of 2023-2033. Rising prevalence of ASDs, increasing investment in ASD R&D, and a solid product pipeline are some of the factors contributing to the growth of the market.
In addition, extensive research activities carried out by organizations and increasing public knowledge of diseases and treatment options are other factors supporting the growth of the market. However, the high cost of diagnosing and treating autism spectrum disorders and stringent product approval laws are expected to hamper growth.
Extensive research activities conducted by organizations to evaluate the efficacy and safety of medicines for ASD patients are expected to drive the growth of the market during the forecast period. The powerful findings of these studies offer new expansion opportunities for the market. For example, Staricula said he successfully completed a Phase 1b trial of the precision medicine candidate STP1 in March 2022, and the results were promising for symptomatic relief in her ASD patient. Therefore, successful conclusions of trials and subsequent product approvals are projected to drive the market.
The market is segmented into selective serotonin reuptake inhibitors, antipsychotics, sleeping pills, stimulants, and others. In 2022, the stimulants segment accounted for the highest revenue share due to patient availability and accessibility of medicines. Several stimulants have been approved by the US FDA for the treatment of autism patients, including Adderall, Dexedrine, Focalin, Vyvanse, and Ritalin. When properly dosed to patients, these drugs reduce symptoms by 80%. As a result, the superior potency of stimulants can attract new target markets and expand revenue streams. The antipsychotic segment is projected to grow profitably over the forecast period. This increase may be due to the availability of antipsychotic drugs, which are the safest and most efficient treatment options for people with ASD. We have only approved Risperdal and Abilify to treat this condition. Both drugs are mainly used in her ASD patients due to their high safety, efficacy and tolerability compared to other drugs.
The market is segmented into pervasive developmental disorders, autism, Asperger’s syndrome, and others. In the global market, the autism segment accounted for the largest revenue share in 2022 due to the rising prevalence of the disease in various regions of the world. Zynerba Pharmaceuticals estimates that he will have 1.4 million people living with ASD in the US in November 2022. As a result, the patient’s demand for medicines used to treat her ASD symptoms is expected to rise and help generate revenue. Other segments are expected to expand rapidly during the forecast period. According to the Autism Research Institute (ARI), Williams syndrome, Fragile X syndrome, Landau-Kleffner syndrome, Angelman syndrome, Prader-Willi syndrome, Rett syndrome, and tardive dyskinesia are most closely associated with autism. There are seven major obstacles. About 15% of his to 20% of people with fragile X syndrome show ASD-like symptoms, such as hand flapping, odd gestures, and poor eye contact. The segment is therefore expected to be driven by rising numbers of people with autism and late-stage product candidates such as Zygel and his STX209 (albaclofen).
By distribution channel
The market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. In 2022, the retail pharmacy segment accounted for the largest revenue share due to the wide availability of medicines such as stimulants, anticonvulsants, tricyclic antidepressants, SSRIs, and anxiety medications at retail pharmacies. According to a June 2021 article, 30% to 50% of all ASD patients reported that he was being treated with at least one of the above drugs. As a result, the market is heavily influenced by the increasing number of people with ASD. The hospital pharmacy industry is expected to grow significantly during the forecast period. There is an increasing focus on patient care programs to assist children with ASD, such as the Autism Center’s Partial Hospital Program and Autism Inpatient Care. Rise in drug prescriptions and increasing public knowledge of the condition are further factors driving market expansion.
1. Survey method
2. Introduction: Treatment of Autism Spectrum Disorders
4. Market dynamics
5. Market environment analysis
6. COVID-19 Impact Analysis: Autism Spectrum Disorder Treatment Market
7. Market Analysis by Treatment
8. Market analysis by application
9. Market analysis by distribution channel
8. Regional Market Analysis
9. North America Autism Spectrum Disorder Treatment Market
10. European Autism Spectrum Disorder Treatment Market
11. Asia-Pacific Autism Spectrum Disorder Treatment Market
12. Latin America Autism Spectrum Disorder Treatment Market
13. MEA Autism Spectrum Disorder Treatment Market
14. Competitor Analysis
15. Company Profile
Bristol-Myers Squibb Company
Cure Mark LLC
Eli Lilly and Company
Johnson & Johnson Service Co., Ltd.
F. Hoffmann La Roche
Otsuka Pharmaceutical Co., Ltd.
Axial Therapeutics Inc.
For more information on this report, please visit https://www.researchandmarkets.com/r/1s0tsz.
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. It provides up-to-date data on international and regional markets, key industries, top companies, new products and latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900